Biotech Unsual Volume: Anacor Pharmaceuticals Inc (NASDAQ:ANAC), Albany Molecular Research (NASDAQ:AMRI), Verastem Inc (NASDAQ:VSTM), Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Anacor Pharmaceuticals Inc (NASDAQ:ANAC) announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) weekly performance is -4.06%. On last trading day company shares ended up $17.01. Analysts mean target price for the company is $26.50. Anacor Pharmaceuticals Inc (NASDAQ:ANAC) distance from 50-day simple moving average (SMA50) is 6.99%.

Albany Molecular Research, Inc. (NASDAQ:AMRI) reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. Analysts expect that Albany Molecular Research will post $0.92 EPS for the current fiscal year. Albany Molecular Research, Inc. (NASDAQ:AMRI) shares fell -1.12% in last trading session and ended the day on $21.26. AMRI Gross Margin is 27.80% and its return on assets is 2.60%. Albany Molecular Research, Inc. (NASDAQ:AMRI) quarterly performance is 32.05%.

Verastem Inc (NASDAQ:VSTM) announced that it will ring the Closing Bell at the NASDAQ MarketSite in Times Square, New York City, on Thursday, July 10, 2014, at 4:00 p.m. ET. Verastem Inc (NASDAQ:VSTM) shares moved down -6.12% in last trading session and was closed at $8.44, while trading in range of $8.05 – $8.93. Verastem Inc (NASDAQ:VSTM) year to date (YTD) performance is -25.96%.

On 18 JUNE Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) said it is up after the news of the company’s initiation of phase-II trials for its lead drug candidate KRN23, which is a monoclonal antibody for X-linked Hypophosphatemia (XLH). Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) ended the last trading day at $41.40. Company weekly volatility is calculated as 6.94% and price to cash ratio as 7.52. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) showed a negative weekly performance of -7.77%.